Drugs / TMC310911
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04547894 | Nov → Dec 2020 | — | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00908414 | May → Oct 2009 | HIV infectious disease | Tibotec Pharmaceuticals, Ireland | Withdrawn | No outcome recorded |
| Phase 1 | NCT00838760 | Feb → Oct 2009 | — | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00838162 | Jun → Aug 2009 | HIV infectious disease | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04261907 | Feb → Apr 2020 | COVID-19 | First Affiliated Hospital of Zhejiang University | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TMC310911 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00838760 ↗ |
| Known as | ASC09 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04261907 ↗ |
| Modality | Small molecule | — CHEMBL4756129 ↗ |
| Route | Oral | “TMC310911 75 mg twice daily orally (by mouth) on Days 1 to 14.” NCT00838162 ↗ |